抗癌药PD-1单抗独撑大局,君实生物去年营收近20亿,大单品“依赖症”何解?

时代周报
28 Mar

图片来源:图虫创意得益于拳头产品特瑞普利单抗(商品名:拓益)的销售拉动,君实生物(01877.HK;688180.SH)2024年亏损大幅收窄。3月27日晚间,君实生物发布2024年年度报告。2024年,君实生物实现营收19.48亿元,同比增长29.67%;归母净亏损为12.81亿元,与上年同期相比收窄了43.90%。截至目前,君实生物商业化产品已经有4款,分别是特瑞普利单抗注射液、阿达木单抗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10